CSF1: Potential Drug Target and Biomarker for Various Diseases

Target Name: CLPSL1

NCBI ID: G340204

CLPSL1

CSF1: Potential Drug Target and Biomarker for Various Diseases

CLPSL1 (C6orf127) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. CLPSL1 is located on chromosome 6 and encodes a protein known as CSF1.

CSF1 is a cytoskeletal protein that is involved in the structure and function of cells. It is expressed in a wide range of tissues and cells, including brain, spinal cord, and blood cells. CSF1 has been shown to play a role in the development and progression of various diseases, including cancer.

One of the key functions of CSF1 is its ability to promote the growth and survival of cancer cells. It has been shown to promote the formation of cancer stem cells, which are cells that have the ability to give rise to all types of cancer. CSF1 has also been shown to contribute to the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

CLPSL1 has also been shown to play a role in the development of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. It has been shown to contribute to the development of diseases that affect the skin, such as psoriasis and dermatitis.

In addition to its role in disease, CLPSL1 has also been shown to be a potential drug target. Researchers have identified several potential drug targets for CSF1, including those that target its role in cancer, neurodegenerative diseases, and autoimmune diseases.

One of the most promising potential drug targets for CSF1 is its role in the development of cancer. Researchers have identified several compounds that have been shown to inhibit CSF1's activity, leading to the potential for these compounds to be used as anti-cancer drugs. These compounds have been shown to be effective in preclinical studies, and further testing is being done to determine their effectiveness in clinical trials.

Another potential drug target for CSF1 is its role in neurodegenerative diseases. Researchers have identified several compounds that have been shown to inhibit CSF1's activity in neurodegenerative diseases, leading to the potential for these compounds to be used as neurodegenerative disease treatments. These compounds have been shown to be effective in preclinical studies, and further testing is being done to determine their effectiveness in clinical trials.

In addition to its potential as a drug target, CLPSL1 has also been shown to be a potential biomarker for various diseases. Its expression has been shown to be elevated in a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. This suggests that CLPSL1 may be a useful biomarker for these diseases, and could be used as a target for diagnostic tests.

Overall, CLPSL1 is a gene that has the potential to be a drug target and biomarker for a wide range of diseases. Further research is needed to fully understand its role in these diseases and to develop effective treatments.

Protein Name: Colipase Like 1

The "CLPSL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLPSL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets